头颈肿瘤精准放疗:基因组学,影像组学&免疫学( 二 )

英文原文

Precision Radiotherapy Approaches in Head and Neck Cancers-A Tripartite Marriage of Genomics, Radiomics, and Immunologics

Melvin Lee Kiang Chua

Clinician-Scientist, Consultant, Division of Radiation Oncology, National Cancer Centre Singapore

Topic: Precision Radiotherapy in Head and Neck Cancers: Genomics, Radiomics & Immunologics

Professor Melvin demonstrated the precision radiotherapy (RT) approaches for head and neck cancers (HNC) based on genomics, radiomics and immunologics. He emphasized the landscape change of HNC, especially the epidemic of human papilloma virus-positive oropharynx squamous cell carcinoma (HPV+ OPSCC). Virus-associated HNC is considered to be different from non-virus-associated HNC, and they found commonalities of genetic changes between TCGA HP+ HNC and Singapore Epstein-Barr virus-positive nasopharyngeal carcinoma (EBV+ NPC). Revised stage classification for HPV+ OPSCC had been proposed, but it has not yet been translated to a change in treatment paradigm for this disease. As for optimal RT dose fractionation, reported 5-year overall survival benefit of 8% with hyperfraction seemed equivalent to that from chemo-RT combination in Meta analysis. Hyperfraction RT might be a way to improve disease control for advanced disease unsuitable to receive chemo-radiotherapy. Recently, a novel precision RT concept, known as adaptive RT, has been proposed for improving the therapeutic ratio. The feasibility of adaptive RT is related to the onset of molecular and functional imaging, which offers information on molecular architecture of the tumour. Radiomics is a novel high throughput feature extraction and selection workflow to derive signatures for clinical prognostication and adapting RT based on real-time tumour changes. Additionally, the acute enthusiasm to incorporate immunotherapy in the management of cancers has also prompted the utility of immunotherapy-RT in HNC. Recent data suggests that genomics and radiomics have the potential to inform on the molecular processes underpinning responses to immunotherapy, and thereby facilitate better patient stratification.